Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)

Inclusion Criteria

1. Healthy child of either gender, who has received a complete 3-dose primary series or acomplete 2 dose primary series followed by a toddler dose with VAXELIS or INFANRIXhexa as part of the V419-007 or V419-008 study respectively.

2. Informed consent signed by the participant's parent(s) or legal representative.

Exclusion Criteria:

1. Participant who has received any dose of hepatitis B (HB)-containing vaccine at anytime other than study vaccine in V419-007 or V419-008 study.

2. Participant with a history of diagnosis (clinical, serological or microbiological) ofHB virus infection of the V419-007 or V419-008 study.

3. Participant who has received any dose of pertussis-containing vaccine after completionof the V419-008 study.

4. Participant with a history of diagnosis (clinical, serological or microbiological) ofinfection due to pertussis after completion of V419-008 study.

5. Participation at the time of study enrolment or in the 4 weeks preceding the studyenrolment in another clinical study investigating a vaccine, drug medical device, ormedical procedure*.

6. Participant who received immunoglobulins, blood or blood-derived products within 3months prior to inclusion*.

7. Receipt of immunosuppressive therapy or other immune-modifying drugs, such asanti-cancer chemotherapy or radiation therapy since completion of V419-007 or V419-008studies.

8. Participant with suspected or known blood dyscrasias, leukemia, lymphomas of any typeor other malignant neoplasms affecting the haematopietic and lymphatic systems sincecompletion of V419-007 or V419-008 studies.

• Criteria 5 and 6 are temporary exclusion criteria. If a participant meetscriteria 5 and/or 6 at the time of Visit 1, a further appointment is to bescheduled to reassess the participant's eligibility.